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The Artificial Pancreas Todayt 
lames F. McMurry, Jr, MD" 
An artificial pancreas is now available in selected centers 
for clinical use in blood glucose control. With informa-
tion derived from 24-30 hours of "closed-loop" insulin 
administration by means of the artificial pancreas, sub-
cutaneous insulin doses may be determined for insulin-
dependent diabetic patients. Eleven poorly controlled 
diabetic patients had their insulin doses reevaluated 
with the artificial pancreas. Ten of 11 patients showed 
improved glucose control when their insulin doses were 
modified by this method. 
I n this electronic age of personal computers, computer-
ized tomography, and other computerized devices, it is 
no surprise to f ind computers extended to the treatment 
of diabetes. A computerized artificial pancreas is now 
available for use in the hospital. This paper reviews the 
development and operation of the artificial pancreas 
and focuses on the author's use ofthis new instrument to 
determine insulin doses for diabetic patients. 
Confusion has recently arisen because portable insulin 
pumps worn on the belt have been described as open-
loop devices and as an artificial pancreas. Two classical 
engineering terms for control systems, "c losed" and 
"open- loop, " have become popular in describing insulin 
delivery. It is important to clarify this terminology. A 
"c losed- loop" system is exemplif ied by the common 
household thermostat and the furnace. When the oper-
ation of the furnace raises the temperature, the heat of 
the room is sensed by a temperature-responsive ther-
mostat. At a preset point, the heat causes the thermostat 
to turn the furnace off. As the temperature drops, the 
thermostat senses the cooling and then turns the heat 
back on (Fig. 1). This example of closed-loop feedback 
control of the operation of the household furnace may 
be contrasted with the simple on-off switch of an electric 
heater, which is an example of open- loop control. When 
the heater is on , and one becomes too warm, it may be 
turned off; or the heater may be turned on i f the room is 
too cold. This simple heater supplies heat, but it requires 
the constant attention of the person who serves as sen-
sor and controller to operate the system. 
The normal, human pancreatic islet cells perform the 
sensor and control ler functions for the blood glucose 
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The sensor/contro l ler of the c losed- loop system is the key di f ference 
between the two systems. 
system. However, in the person with diabetes, the auto-
matic closed-loop system is deficient f rom loss of the 
islet cell as both glucose sensor and control ler, as well as 
insulin supplier. This loss of automaticity is a greater 
problem than the loss of the insulin supply itself. 
Al though the injection needle is an irritating mode of 
insulin supply, even more frustrating is the constant 
mental effort required to control the blood sugar. Only 
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an insulin delivery system which senses the blood glu-
cose level, automatically determines the appropriate 
dose, and then delivers that dose is a true closed-loop 
system. An artificial pancreas is a closed-loop system. 
Development of the Artificial Pancreas 
The technology for developing the ideal artificial pan-
creas could learn about size, durabil i ty, and monitor ing 
of funct ion f rom the advances in cardiac pacemaker 
technology. Diabetic patients would like a small, com-
pact, implanted device that leaves no unsightly bulges. 
This instrument would sense the blood glucose accu-
rately, calculate a proper insulin dose, administer the 
insulin into the portal vein (the normal venous drainage 
o f the islet cells), and operate for long periods of t ime on 
a small set of batteries. It would be extremely reliable, 
allow the person to eat large amounts of starch or glu-
cose, and maintain the blood glucose at normal levels. 
Since no "overshoot ing" of insulin administration would 
occur, hypoglycemia could be strictly avoided. How-
ever,this ideal artificial pancreas has notyet been devel-
oped. While the problems of size and dose calculation 
have been successfully resolved, the glucose-monitoring 
system remains a major technical stumbling block. 
Around 1970, glucose-monitor ing instruments were 
borrowed from the clinical laboratory, and efforts focused 
on the problems of calculating the appropriate insulin 
dose. Pumps were used to move blood from the patient's 
vein to the glucose-measuring instrument, and blood 
glucose could be measured for a few hours at a t ime. A 
computer received the glucose measurement, calcu-
lated an insulin dose, and control led a syringe pump 
which administered the insulin. 
Years of research were spent developing better comput-
er programs to calculate the appropriate insulin dose. 
All computers operate on instructions f rom their pro-
grams in the form of mathematical formulas and logical 
statements (if " x " , then do " y " ) . This combination of 
repeated logical and mathematical instructions forms 
the algorithm for the computer program. Through years 
of work on the experimental artificial pancreas, algo-
rithms for insulin dosage calculations were adjusted 
repeatedly until smooth glucose control was achieved. 
Concurrent technical efforts were aimed at miniaturiza-
t ion. Dur ingthe mid-1970s,the paraphernalia associated 
with the experimental artificial pancreas was so bulky 
that it f i l led most of a room. But through microelectron-
ics, the artificial pancreas has been miniaturized f rom a 
roomful of equipment to a bedside, cart-mounted 
device (Fig. 2). In 1980, the Ames division of Miles Labor-
atories received permission f rom the U.S. Food and 
Drug Administration to sell its "Biostator Glucose-
Control led Insulin Infusion System." A year later, Ames 
released its second artificial pancreas, the "Biostator 
Glucose Control ler ," which is similar to the first, though 
less complex. 
Much of the size reduction of these instruments was 
achieved by electronic circuit boards with a computer 
on a chip. In addit ion, electronic safety interlocks pre-
vent control buttons from being activated in incorrect 
sequence. An alarm sounds i f the blood glucose drops to 
40 mg/d l or even drops quickly, and 20% dextrose is 
infused if the blood glucose falls below an adjustable 
preset limit. At each minute the device prints the t ime, 
the blood glucose level, the insulin infused for the min-
ute, and the dextrose infused (if any) for that minute. 
Blood glucose measurement by the Biostator instrument 
requires the withdrawal of blood from a large peripheral 
vein at the rate of only 2 ml per hour. Simultaneous 
administration of a small amount of heparinized saline 
solution inhibits clotting in the blood withdrawal line. 
Fig. 2 
Patient attached to the Biostator artif icial pancreas, which is moved to 
the bedside on its wheeled cart. One needle is placed in a large vein for 
b lood w i thdrawal to measure glucose. Insulin (or dextrose) is adminis-
tered through a smaller needle in a vein of the opposite arm. The 
printer generates a page (60 lines) of data each hour. 
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The blood and heparinized saline mix near the t ip o f the 
needle, and this mixture is pumped into the instrument. 
After further d i lu t ion, the blood mixture passes through 
the glucose sensor, where glucose diffuses into a mem-
brane and reacts with glucose oxidase to produce hydro-
gen peroxide in proport ion to the amount of glucose 
present. In turn, the hydrogen peroxide is measured by a 
silver-platinum electrode which converts oxygen from 
hydrogen peroxide to a proport ionate amount of elec-
trical current. This method of measurement is accurate 
over a range of 50-500 mg/d l . 
Once an accurate blood glucose measurement has been 
made, the Biostator calculates an insulin dose and 
pumps it through an intravenous line to the patient's 
vein. The insulin dose is recalculated each minute, and 
calculation takes into account not only the current 
blood glucose level, but also the trend of the glucose 
values of the preceding five minutes. The insulin deliv-
ery pump can vary the dose from 10 to 300 milliunits per 
minute, and by " remember ing " a fractional dose, the 
pump can administer fewer than 10 milliunits. Ten mil l i -
units can beg i venoneminu teand none the next, fo ran 
average rate of five mill iunits per minute. This wide 
variation in insulin infusion allows large amounts to be 
administered when the blood glucose rises quickly after 
a meal, but a drastically reduced dose when the blood 
glucose levels off and begins to fall (Fig. 3). 
Further miniaturization of the artificial pancreas has 
been reported from Japan. The assembly of the glucose 
electrode into the tip of an 18-gauge needle was de-
scribed in 1981 (1), and reduction of the size of the 
computat ion and pump mechanism was reported in 
1982 (2). This size reduction allows the device to fit in a 
large pocket. In November 1982, a Japanese device 
achieved good glucose control in diabetic dogs for three 
to four days by a needle electrode inserted into the 
subcutaneous tissue. Because the interface between the 
machine and blood or tissue f luid deteriorates fairly 
rapidly, the response of the glucose electrode deterio-
rated on the third and fourth days (3). At present, the 
membrane of the glucose-measuring section o f the Bio-
stator devices has a useful life of about 48 hours. 
The Biostator in Surgery and Obstetrics 
The stress of surgery produces insulin resistance even in 
normal persons, and infusion of glucose-containing 
fluids may evoke transient hyperglycemia (4). Animal 
studies show that wound healing is impaired in the pres-
ence of hyperglycemia (5). This risk is even greater for 
the diabetic patient, and many regimens have been pro-
posed to treat the diabetic surgical patient. Several 
groups have demonstrated that the Biostator is effective 
in control l ing glucose levels dur ing general anesthesia 
and major procedures (6,8). The rapid drop in insulin 
requirements that often occurs dur ing an obstetrical 
delivery of thediabet icwoman can be managed smoothly 
with the Biostator, despite a tenfold change in insulin 
requirements (7). 
The Biostator in Determining Insulin Doses 
Many reports (9-16) have demonstrated that using the 
artificial pancreas yields data on insulin administration 
which can then be used to calculate a subcutaneous 
insulin dose for a diabetic patient. Since the Biostator 
prints out the amount of insulin used each minute, the 
insulin requirements for meals and between meals 
(basal) may be assessed. 
Methods 
The Biostator protocol 
To use the Biostator to determine subcutaneous doses, a 
method is needed to determine which insulin data 
" b e l o n g " to a meal. Though insulin is infused as a per-
son begins eating, blood glucose or insulin need does 
not increase immediately. Addit ionally, the blood glu-
cose level may remain high (and insulin infusion high) 
for a t ime after a person completes eating. Thus, using 
only the data on the amount of insulin infused during 
food consumption would produce an inaccurate esti-
mate of the insulin required for that meal. Therefore, a 
repeatable mathematical def ini t ion should be based on 
the change in blood glucose that occurs with the meal 
(Fig. 3). The basal insulin requirement (units/hour) can 
Fig. 3 
Display f rom the Apple-Bios program il lustrating a smooth glucose 
response to two ingested meals, achieved by infusing large amounts of 
insul in early, then reduc ing the infusion rate prompt ly . Both b lood 
glucose in m g / d l and insulin infusion rate in m U / m i n are shown on the 
abscissa; t ime in minutes is shown on the ordinate. 
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then be subtracted from the total insulin infused during 
this absorption period to yield the net amount of insulin 
required for that particular meal. 
In this study, we evaluated five ways to define this 
absorption period (Table I). For each proposed method, 
the times were calculated for that meal, and all times 
werethen normalized by setting the graphic estimate to 
12:30 pm and adjusting the other times to this base 
method. As shown in Table I, most of the potential 
methods appear workable and agreed well in minutes. 
The insulin based method proved most sensitive (earliest 
t ime), but the primary event is a rise in blood glucose 
levels. Since an insulin change is secondary, a glucose-
based definit ion was adopted. For subsequent studies, 
the start of the absorption period was defined as the 
minute at which the blood glucose concentration rose 
to two standard deviations above the mean glucose 
(calculated from the first ten minutes that the patient 
began eating). 
The end of the absorption period is determined in sim-
ilar fashion. The glucose level may plateau after a meal at 
a slightly higher level than before the meal; a post-meal 
plateau is found, and the end o f the absorption period is 
defined as the minute at which the glucose level first 
reaches the pre-meal level or the mean of ten glucose 
values in this plateau (Fig. 4). 
A microcomputer (Apple II Plus) connected to the print-
er of the Biostator transfers the printed data to the com-
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Absorption period indicates a lag between the times of eating and the 
beginning rise in blood glucose. A standardized def ini t ion of the absorp-
tion period was based on a change in blood glucose concentration. 
TABLE I 
Beginning of Meal Absorpt ion 
Meal Method A Method B Method C Method D Method E Range 
1 12:30 p m 12:41 p m 12:31 p m 12:37 p m 12:39 p m 11 
2 12:30 29 33 29 32 4 
3 12:30 34 35 33 34 4 
4 12:30 J9 38 38 i9 9 
S 12:30 24 24 25 19 11 
b 12:30 32 32 31 20 12 
7 12:30 22 28 22 23 8 
8 12:30 29 30 28 M) 2 
9 12:30 35 33 34 31 5 
10 12:30 31 35 32 33 5 
11 12:30 27 33 27 27 6 
I J 12:30 35 34 34 31 5 
1 12:30 32 32 32 32 2 
14 12:30 34 28 28 29 6 
15 12:30 29 32 28 26 6 
16 12:30 ife 36 34 30 6 
1EAN 12:30 p m 12:31.9 12:32.1 12:30.8 12:29.7 fe,4 
SU - 5.4 3.4 4.3 5.7 3.1 
SEM 1,3 0,9 1,1 1.4 0.1 
Method A: Blood glucose values were plotted, and straight lines were 
visually fit, using basal glucose values and rise of glucose 
concentration. Time was indicated by the intercept of two 
lines. 
Method B: Mean and standard deviations were determined for first 10 
blood glucose values as subject ate the meal; the first actual 
blood glucose value greater than mean plus 3 SD was found. 
Method C: First actual blood glucose value exceeding mean plus 5 
mg/dl . 
Method D: First actual blood glucose value exceeding mean plus 2 SD. 
Method E: First actual insulin delivery rate exceeding mean plus 2 SD: 
mean of the first 10 insulin rates as subject ate the meal. 
Each set of data was transformed by using the visually fit straight lines 
(Method A) as the base time of 12:30 pm; times for each additional method 
were adjusted by the same number of minutes. 
puter and stores it on a magnetic disk. For this study, a 
program was wri t ten to permit us to calculate these 
insulin doses for meals quickly and conveniently (18). 
The basal insulin requirement (units/hour) is calculated 
by averaging the insulin required during the night f rom 
midnight to 5 am. Figures for this basal requirement and 
the summed meal requirements for a 24-hour period are 
added together to determine the total insulin needed 
for a day. Over-insulinization occurs when insulin is 
given by the intravenous route (17). Thus, in planning a 
subcutaneous dose of insulin for a patient, one must 
discount, by an appropriate factor, the Biostator-derived 
amount of insulin to convert f rom the intravenous to the 
subcutaneous dose. We reduce insulin amounts to 80% 
to transfer f rom the intravenous to the subcutaneous 
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dose. Previous investigators have used 74-90% of the 
intravenous dose (11,12). 
Once appropriate insulin amounts for basal and individ-
ual meal doses have been found, further determination 
of the subcutaneous dose follows these general princi-
ples: the morning dose of intermediate insulin should 
supply the suppertime dose and about two thirds o f t he 
basal dose; a morning dose of regular insulin supplies 
the luncht ime requirement and about one half of the 
breakfast requirement; and an evening dose of inter-
mediate insulin provides about one half of the breakfast 
requirement and about one third of the basal requirement. 
A patient is connected to the Biostator early in the morn-
ing. No intermediate insulin is given on the evening 
before, but small doses of regular insulin may be given 
subcutaneously or intravenously. The Biostator glucose 
controller is calibrated according to manufacturer's 
instructions. It is adjusted to discontinue insulin infusion 
if the blood glucose falls below 80 mg/d l and to infuse 
20% dextrose i f the blood glucose falls below 60 mg/d l . A 
maximum of 305 mU of insulin and 400 mg of dextrose 
can be infused in a one-minute period. Patients are 
connected to the Biostator for 26-30 hours for this study. 
Because two to four hours are needed to stabilize 
patients on the artificial pancreas initially, and because 
of the possibility of the continued effect of subcutane-
ous intermediate insulin given the preceding morning, 
the insulin infused for the noon meal on the first day is 
not used to calculate the insulin requirement. After the 
patient's blood glucose level stabilizes fol lowing the 
noon meal on the second day, the patient is discon-
nected from the Biostator. This second noon meal is 
used in dosage calculations. 
Patients 
We studied 11 insulin-dependent diabetic persons 
admitted to the hospital for the purpose of improving 
their glucose regulation. None had an acute illness. All 
received a diet fairly high in carbohydrate and plant 
fiber (50-55% carbohydrate, 20% protein, and 25-30% 
fat). Three patients were admitted to initiate continuous 
subcutaneous insulin infusion (insulin pump therapy). 
The patients ranged in age from 19-60 years (mean: 31.6 
years) and had had diabetes mellitus from four to 24 
years (mean: 13.5 years). Hemoglobin Al values on 
admission ranged from 7.8% to 20.9% (mean: 12.5%). 
Each patient was taking insulin two to three times daily 
before they were admitted. 
M-value and MG 
Schlichtkrull, et al (19) reported the development of 
the " M - v a l u e " as an index of glucose control that re-
flects mean glucose but also increases with hypogly-
cemic values. We used the Service (20,21) modification 
of Schlichtkrull's formula in this study. We obtained 
three to six serum glucose values during the first 24 
hours of hospitalization (admission) and during the last 
24 hours of hospitalization (discharge) in order to calcu-
late the mean glucose (AMG and DMG) and the M-value 
(A-M and D-M). 
Statistical analysis 
Calculations of mean, standard deviation, and standard 
error of the mean were performed with the Statistical 
Analysis System program (22) at the University of Ken-
tucky Computing Center. 
Results 
The Biostator protocol did not predict insulin doses per-
fectly. After Biostator treatment, patients required two 
to 11 days in the hospital to stabilize and further manipu-
late the subcutaneous dose. In six of 11 persons, the 
Biostator predicted the final insulin dose within 10%. In 
two patients, the predict ion was overestimated by 20-
30%, and in two patients it was underestimated by 20-
30%. In one very anxious patient, the predicted dosewas 
overestimated by one and one half times (Table II). 
TABLE II 
Insulin and Glucose Results 
Pts AM DM AMG DMG Al Bi Dl BDI ADI 
1 106 58 238 190 60 41 42 98 143 
2 70 6 222 121 39 64 64 100 61 
3 86 46 244 196 33 30 30 100 110 
4 128 106 272 209 58 53 76 70 76 
5 45 5,3 123 188 50 30 28 107 179 
6 154 41 268 155 40 47 38 124 105 
7 124 10 270 79 40 70 45 156 89 
8 75 42 178 145 155 60 60 100 258 
9 6 3 118 93 59 42 54 78 109 
10 106 105 256 217 19 18 14 129 136 
Tl 37 16 172 136 50 49 48 102 104 
MEAN 85.2 44.2 214.6 157.2 54.8 45.8 45.4 105.7 124.6 
SD 44.1 35.9 57.7 46.8 35.5 15.8 17.8 23.7 54.9 
SE 13.3 10.8 17.4 14.1 10.7 4,8 5.4 7.1 16.6 
A M : Admission M-value D M : Discharge M-value 
A M G : Admission Mean Glucose D M G : Discharge Mean Glucose 
(mg/dl) 
A l : Admission Insulin Dose 
(units/day) 
D l : Discharge Insulin Dose 
(units/day) 
ADI : Ratio of A I / D I (%) 
(mg/dl) 
Bl: Biostator-predicted Insulin 
dose (units/day) 
BDI: Ratio of BI /DI (%) 
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These patients obtained good improvement in glucose 
control . Admission mean glucose levels fell f rom 215 
mg/d l to 157 mg/d l , and M-values also fell (85-44). All 
but one patient improved; the M-value of this patient 
rose slightly. 
At hospital admission, the mean insulin was 125% of the 
discharge dose; eight of 11 were over-insulinized on 
admission. A change from admission to discharge insulin 
doses of 20% or greater was needed in six of 11 patients; 
in the remainder, the Biostator data suggested a change 
in t iming of insulin administration rather than a major 
alteratio n in total insulin doses. 
Discussion 
This study conf irmed the usefulness of the Biostator in 
planning insulin doses for diabetics and the importance 
of reducing the intravenous Biostator dose when this is 
transferred to a subcutaneous dose. Using 80% of this 
intravenous dose appears reasonable. When one excep-
tional patient (#9) was removed f rom the analysis, this 
reduction in dose to 80% resulted in a Biostator predic-
t ion of 99.7% of the mean discharge insulin dose in the 
patient group. White, et al (23) recently corroborated 
our results; their patients' nocturnal subcutaneous insulin 
requirements were 81% of the intravenous insulin dose 
required in an overnight infusion protocol. 
Ratzmann, et al (16) recommended that the operating 
characteristics of the Biostator be changed so that the 
targeted blood glucose levels during Biostator treatment 
would be raised from 80 to 130 mg/d l to better predict 
the required insulin change needed in their unstable, 
insulin-dependent patients. In their study, the patient's 
usual subcutaneous dosage was cont inued dur ing Bio-
stator treatment. From the Biostator they learned that 
additional insulin was required in nine of 11 patients 
studied. However, in our series, eight of 11 patients 
actually required less insulin. The use of concomitant 
subcutaneous insulin and Biostator treatment would not 
predict doses for patients who were already over-
insulinized. For this reason, it is recommended that 
patients be removed f rom their usual subcutaneous 
insulin when the Biostator is used to determine insulin 
dosages and that the targeted blood glucose level o f t he 
instrument be set to 80 mg/d l . 
The Future 
Alternative forms of insulin administration either from 
multiple injections of regular insulin or from compact 
insulin pumps show promise of improving glucose regu-
lation (24). The introduction of home blood glucose 
monitoring has also improved day-to-day glucose regula-
t ion. It is diff icult to say which of these developments 
have been more important. In all open-loop methods of 
insulin administrat ion, the patient's personal effort 
remains intensive. If automatic glucose regulation can 
remove this burden, it is a reasonable alternative worthy 
of a large expenditure of money. It has been demon-
strated that an elegant, implanted open-loop pump can 
improve glucose regulation by delivering insulin to the 
portal circulation via absorption from the peritoneal cav-
ity (26). Biostator instruments have demonstrated that 
these algorithms efficiently control the administration of 
insulin based upon a blood glucose measurement. Thus, 
the future of closed-loop devices looks bright. 
Resolving the problems of a long-lasting, reliable glu-
cose sensor remains the greatest obstacle (25). Albisser 
(27) has commented that good glucose control may not 
require a glucose sensor; he suggests that a clock timer 
on an insulin pump wil l suffice. However, the person 
with diabetes would remain dependent on the clock for 
t iming of meals. Thus, the desire for an implanted, fully 
automatic method of insulin delivery, or artificial pan-
creas, remains. Solving the problems of islet cell trans-
plantation would be an equally effective answer for the 
reestablishment of automatic blood glucose control. We 
might characterizefuture research as a race between the 
cell biologist/ immunologist work ing on islet cell trans-
plants and the electr ical/biomedical engineer working 
on implantable versions of the art i f icial pancreas. 
Al though one direction of research effort may win , the 
real beneficiaries wil l be mill ions of persons with dia-
betes mellitus. 
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